EP2097084B1 - Carboxamid 4-[(4-pyridyl)amino] pyrimidine zur behandlung von hepatitis c - Google Patents

Carboxamid 4-[(4-pyridyl)amino] pyrimidine zur behandlung von hepatitis c Download PDF

Info

Publication number
EP2097084B1
EP2097084B1 EP07820916.0A EP07820916A EP2097084B1 EP 2097084 B1 EP2097084 B1 EP 2097084B1 EP 07820916 A EP07820916 A EP 07820916A EP 2097084 B1 EP2097084 B1 EP 2097084B1
Authority
EP
European Patent Office
Prior art keywords
group
optionally substituted
alkyl
ring
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP07820916.0A
Other languages
English (en)
French (fr)
Other versions
EP2097084A2 (de
Inventor
Pierre Jean-Marie Bernard Raboisson
Oliver Lenz
Tse-I Lin
Kenneth Simmen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen R&D Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R&D Ireland ULC filed Critical Janssen R&D Ireland ULC
Priority to EP07820916.0A priority Critical patent/EP2097084B1/de
Publication of EP2097084A2 publication Critical patent/EP2097084A2/de
Application granted granted Critical
Publication of EP2097084B1 publication Critical patent/EP2097084B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]-pyrimidines as inhibitors of HCV replication in the manufacture of pharmaceutical compositions to treat or combat an infection with hepatitis C virus.
  • Hepatitis C virus is the leading cause of chronic liver disease worldwide and has become a focus of considerable medical research.
  • HCV is a member of the Flaviviridae family of viruses in the hepacivirus genus, and is closely related to the flavivirus genus, which includes a number of viruses implicated in human disease, such as dengue virus and yellow fever virus, and to the animal pestivirus family, which includes bovine viral diarrhea virus (BVDV).
  • BVDV bovine viral diarrhea virus
  • HCV type 1 is the predominant genotype in the US and Europe. For instance, HCV type 1 accounts for 70 to 75 percent of all HCV infections in the United States. The extensive genetic heterogeneity of HCV has important diagnostic and clinical implications, perhaps explaining difficulties in vaccine development and the lack of response to therapy. An estimated 170 million persons worldwide are infected with hepatitis C virus (HCV).
  • HCV hepatitis C virus
  • HCV replicates preferentially in hepatocytes but is not directly cytopathic, leading to persistent infection.
  • the lack of a vigorous T-lymphocyte response and the high propensity of the virus to mutate appear to promote a high rate of chronic infection.
  • subsequent to an initial acute infection a majority of infected individuals develop chronic hepatitis, which can progress to liver fibrosis leading to cirrhosis, end-stage liver disease, and HCC (hepatocellular carcinoma) ( National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. Hepatology, 36, 5 Suppl. S3-S20, 2002 ).
  • HCV Hepatitis C virus
  • HCV RNA can be detected in blood in 1-3 weeks. Within an average of 50 days virtually all patients develop liver cell injury. The majority of patients are asymptomatic and anicteric. Only 25-35 percent develop malaise, weakness, or anorexia, and some become icteric.
  • Antibodies to HCV (anti-HCV) almost invariably become detectable during the course of illness. Anti-HCV can be detected in 50-70 percent of patients at the onset of symptoms and in approximately 90 percent of patients 3 months after onset of infection. HCV infection is self-limited in only 15 percent of cases. Recovery is characterized by disappearance of HCV RNA from blood and return of liver enzymes to normal.
  • Chronic hepatitis C is typically an insidious process, progressing, if at all, at a slow rate without symptoms or physical signs in the majority of patients during the first two decades after infection. Symptoms first appear in many patients with chronic hepatitis C at the time of development of advanced liver disease.
  • inflammatory cells infiltrate the portal tracts and may also collect in small clusters in the parenchyma.
  • the latter instance is usually accompanied by focal liver cell necrosis.
  • the margin of the parenchyma and portal tracts may become inflamed, with liver cell necrosis at this site (interface hepatitis). If and when the disease progresses, the inflammation and liver cell death may lead to fibrosis. Mild fibrosis is confined to the portal tracts and immediately adjacent parenchyma. More severe fibrosis leads to bridging between portal tracts and between portal tracts and hepatic veins.
  • Such fibrosis can progress to cirrhosis, defined as a state of diffuse fibrosis in which fibrous septae separate clusters of liver cells into nodules. The extent of fibrosis determines the stage of disease and can be reliably assessed. Severe fibrosis and necroinflammatory changes predict progression to cirrhosis. Once cirrhosis is established, complications can ensue that are secondary to liver failure and/or to portal hypertension, such as jaundice, ascites, variceal hemorrhage, and encephalopathy. The development of any of these complications marks the transition from a compensated to a decompensated cirrhosis.
  • Chronic hepatitis C infection leads to cirrhosis in at least 20 percent of patients within 2 decades of the onset of infection. Cirrhosis and end-stage liver disease may occasionally develop rapidly, especially among patients with concomitant alcohol use. Chronic infection by HCV is associated with an increased risk of liver cancer.
  • the prevailing concept is that hepatocellular carcinoma (HCC) occurs against a background of inflammation and regeneration associated with chronic hepatitis over the course of approximately 3 or more decades. Most cases of HCV-related HCC occur in the presence of cirrhosis.
  • Liver fibrosis is one of the processes that occurs when the liver is damaged. Such damage may be the result of viral activity as explained hereinabove (e.g., chronic hepatitis types B or C) or other liver infections (e.g., parasites, bacteria); chemicals (e.g., pharmaceuticals, recreational drugs, excessive alcohol, exposure to pollutants); immune processes (e.g., autoimmune hepatitis); metabolic disorders (e.g., lipid, glycogen, or metal storage disorders); or cancer growth (primary or secondary liver cancer). Fibrosis is both a sign of liver damage and a potential contributor to liver failure via progressive cirrhosis of the liver.
  • viral activity e.g., chronic hepatitis types B or C
  • other liver infections e.g., parasites, bacteria
  • chemicals e.g., pharmaceuticals, recreational drugs, excessive alcohol, exposure to pollutants
  • immune processes e.g., autoimmune hepatitis
  • metabolic disorders e.g., lipid, glycogen,
  • liver fibrosis may be caused by different etiological agents, including the Hepatitis C virus. Most importantly, liver fibrosis is a specific condition in the disease progression of patients infected with HCV.
  • WO04/024159 discloses substituted pyrimidines and triazines which are useful in the treatment of conditions associated with enhanced TGF ⁇ activity.
  • HCV replication refers to the process of reproducing or making copies of HCV RNA.
  • HCV replication both refers to the replication of the HCV virus as a whole or the replication of the HCV RNA genome.
  • the compounds of the present invention are thus able to treat HCV infected patients at early stages in order to avoid disease progression, thereby avoiding that the patient develops chronic hepatitis, liver fibrosis, cirrhosis, hepatocellular carcinoma (HCC), or death.
  • HCC hepatocellular carcinoma
  • the compounds of the invention are valuable in that they can diminish the HCV viral load of a patient, or can diminish the HCV viral load of a patient to undetected levels.
  • the compounds of the invention herein are derivatives of pyrimidine.
  • PCT publication WO01/47921 describes pyrimidine and triazine compounds that are inhibitors of kinase activities associated with various inflammatory conditions, as opposed to the treatment of fbroproliferative disorders described herein.
  • the above mentioned PCT publication describes the use of the compounds disclosed only for treatment of the inflammatory aspects of certain autoimmune diseases. Further, the compounds described differ from those described herein by virtue of the substitutions required on the pyrimidine nucleus; among other distinctions, the compounds disclosed in the PCT publication do not include phenyl bound directly to the pyrimidine ring.
  • the carboxamide is attached via its carbonyl carbon, and is typically a secondary amide; furthermore, the compounds of the present invention include specific functional groups and substituents particularly on the amide group, that are selected for their ability to reduce metabolism and increase bioavailability of the active species.
  • U.S. Patent No. 6,476,031 also discloses compounds containing a quinazoline ring linked to an aryl group at C-4 of the quinazoline.
  • the compounds are reported to act at the TGF ⁇ site, and some of the compounds include a 4-pyridylamine group at C-4 of the quinazoline.
  • the '031 patent discloses that the aryl group linked to C-4 of the quinazoline is preferably unsubstituted 4-pyridyl, and it does not disclose any compounds where the 4-pyridyl includes an amide substituent such as the ones at the 3-position of the 4-pyridyl group in the compounds of the present invention.
  • the present invention concerns the use of the compound of formula (I) in the manufacture of a medicament for the treatment of an infection with hepatitis C virus by inhibition of HCV replication.
  • the compounds of the invention can be represented by formula (I): wherein Ar represents an optionally substituted phenyl ring;
  • the invention also relates to the use of a compound of formula (I), or their pharmaceutically acceptable salts for the manufacture of a medicament for inhibiting HCV replication.
  • the invention relates to a the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an infection with hepatitis C virus in a warm-blooded animal by inhibiting HCV replication.
  • the compounds of formula (1) show activity against the HCV virus and are therefore useful as a medicament, and in the manufacture of a medicament for preventing, treating or combating an infection with hepatitis C virus other than liver fibrosis by inhibition of HCV replication.
  • the invention provides a method of preventing, treating or combating an infection with hepatitis C virus other than liver fibrosis.
  • hydrocarbyl refers to a C1-C20 hydrocarbon group that may contain alkyl chains, rings, or combinations of chains and rings, and may contain one or more unsaturated and / or aromatic structures, but which contains no heteroatoms unless it is substituted.
  • a hydrocarbyl group may be substituted at any available position with suitable substituents as further described herein.
  • alkyl straight-chain, branched-chain monovalent hydrocarbyl radicals, and combinations of these, which contain only C and H when they are unsubstituted. Examples include methyl, ethyl, isobutyl, 2-propenyl and 3-butynyl.
  • the total number of carbon atoms in each such group is sometimes described herein, e.g. , either as 1-10C or as C1-C10 when the group can contain up to ten carbon atoms.
  • heteroatoms N, O and S typically
  • the numbers describing the group represent the sum of the number of carbon atoms in the group plus the number of such heteroatoms that are included as replacements for carbon atoms.
  • the alkyl, alkenyl and alkynyl substituents of the invention contain 1-10C (alkyl) or 2-10C (alkenyl or alkynyl). Preferably they contain 1-8C (alkyl) or 2-8C (alkenyl or alkynyl). Sometimes they contain 1-4C (alkyl) or 2-4C (alkenyl or alkynyl).
  • a single group can include more than one type of multiple bond, or more than one multiple bond; such groups are included within the definition of the term "alkenyl" when they contain at least one carbon-carbon double bond, and are included within the term "alkynyl" when they contain at least one carbon-carbon triple bond.
  • Alkyl, alkenyl and alkynyl groups are often substituted to the extent that such substitution makes sense chemically.
  • Heteroalkyl “heteroalkenyl”, and “heteroalkynyl” are defined similarly to the corresponding hydrocarbyl (alkyl, alkenyl and alkynyl) groups, but the 'hetero' terms refer to groups that contain 1-3 O, S or N heteroatoms or combinations thereof within the backbone residue; thus at least one carbon atom of a corresponding alkyl, alkenyl, or alkynyl group is replaced by one of the specified heteroatoms to form a heteroalkyl, heteroalkenyl, or heteroalkynyl group.
  • heteroforms of alkyl, alkenyl and alkynyl groups are the same as for the corresponding hydrocarbyl groups, and the substituents that may be present on the heteroforms are the same as those described above for the hydrocarbyl groups.
  • substituents that may be present on the heteroforms are the same as those described above for the hydrocarbyl groups.
  • such groups do not include more than two contiguous heteroatoms except where an oxo group is present on N or S as in a nitro or sulfonyl group.
  • cycloalkyl is used herein to describe a carbocyclic non-aromatic group that is connected via a ring carbon atom
  • cycloalkylalkyl may be used to describe a carbocyclic non-aromatic group that is connected to the molecule through an alkyl linker.
  • heterocyclyl may be used to describe a non-aromatic cyclic group that contains at least one heteroatom as a ring member and that is connected to the molecule via a ring atom, which may be C or N .
  • cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl groups are the same as those described above for alkyl groups. As used herein, these terms also include rings that contain a double bond or two, as long as the ring is not aromatic.
  • acyl encompasses groups comprising an alkyl, alkenyl, alkynyl, aryl or arylalkyl radical attached at one of the two available valence positions of a carbonyl carbon atom
  • heteroacyl refers to the corresponding groups wherein at least one carbon other than the carbonyl carbon has been replaced by a heteroatom chosen from N, O and S.
  • Acyl and heteroacyl groups are bonded to any group or molecule to which they are attached through the open valence of the carbonyl carbon atom. Typically, they are C1-C8 acyl groups, which include formyl, acetyl, pivaloyl, and benzoyl, and C2-C8 heteroacyl groups, which include methoxyacetyl, ethoxycarbonyl, and 4-pyridinoyl.
  • the hydrocarbyl groups, aryl groups, and heteroforms of such groups that comprise an acyl or heteroacyl group can be substituted with the substituents described herein as generally suitable substituents for each of the corresponding component of the acyl or heteroacyl group.
  • Aromaatic moiety or aryl moiety refers to a monocyclic or fused bicyclic moiety having the well-known characteristics of aromaticity; examples include phenyl and naphthyl.
  • heteroaryl refers to such monocyclic or fused bicyclic ring systems which contain as ring members one or more heteroatoms selected from O, S and N. The inclusion of a heteroatom permits aromaticity in 5-membered rings as well as 6-membered rings.
  • Typical heteroaromatic systems include monocyclic C5-C6 aromatic groups such as pyridyl, pyrimidyl, pyrazinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, and imidazolyl and the fused bicyclic moieties formed by fusing one of these monocyclic groups with a phenyl ring or with any of the heteroaromatic monocyclic groups to form a C8-C10 bicyclic group such as indolyl, benzimidazolyl, indazolyl, benzotriazolyl, isoquinolyl, quinolyl, enzothiazolyl, benzofuranyl, pyrazolopyridyl, quinazolinyl, quinoxalinyl and cinnolinyl, Any monocyclic or fused ring bicyclic system which has the characteristics of aromaticity in terms of electron distribution throughout the ring
  • the ring systems contain 5-12 ring member atoms.
  • the monocyclic heteroaryls contain 5-6 ring members, and the bicyclic heteroaryls contain 8-10 ring members.
  • Aryl and heteroaryl moieties may be substituted with a variety of substituents including halo, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, OR, NR 2 , SR, SO 2 R, SO 2 NR 2 , NRSO 2 R, NRCONR 2 , NRCOOR, NRCOR, CN, COOR, CONR 2 , OOCR, COR, and NO 2 , wherein each R is independently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl, and each R is optionally substituted as described above for alkyl groups.
  • arylalkyl and “heteroarylalkyl” refer to aromatic and heteroaromatic ring systems which are bonded to their attachment point through a linking group which is alkylene .
  • the linker is C1-C8 alkyl
  • An aryl or heteroaryl ring in an arylalkyl or heteroarylalkyl group may be substituted with the same substituents described above for aryl groups.
  • an arylalkyl group includes a phenyl ring optionally substituted with the groups defined above for aryl groups and a C1-C4 alkylene that is unsubstituted or is substituted with one or two C1-C4 alkyl groups or heteroalkyl groups .
  • a heteroarylalkyl group preferably includes a C5-C6 monocyclic heteroaryl group that is optionally substituted with the groups described above as substituents typical on aryl groups and a C1-C4 alkylene that is unsubstituted or is substituted with one or two C1-C4 alkyl groups or heteroalkyl groups, or it includes an optionally substituted phenyl ring or C5-C6 monocyclic heteroaryl and a C1-C4 heteroalkylene that is unsubstituted or is substituted with one or two C1-C4 alkyl groups.
  • substituents may be on either the alkyl portion or on the aryl or heteroaryl portion of the group.
  • the substituents optionally present on the alkyl portion are the same as those described above for alkyl groups generally; the substituents optionally present on the aryl or heteroaryl portion are the same as those described above for aryl groups generally.
  • Arylalkyl groups as used herein are hydrocarbyl groups if they are unsubstituted, and are described by the total number of carbon atoms in the ring and the alkylene linker.
  • a benzyl group is a C7-arylalkyl group
  • phenethyl is a C8-arylalkyl.
  • Heteroarylalkyl refers to a moiety comprising an aryl group that is attached through a linking group, and differs from “arylalkyl” in that at least one ring atom of the aryl moiety or one atom in the linking group is a heteroatom selected from N, O and S.
  • the heteroarylalkyl groups are described herein according to the total number of atoms in the ring and linker combined, and heteroaryl groups linked through a hydrocarbyl linker. such as an alkylene.
  • Alkylene refers to a divalent hydrocarbyl group; because it is divalent, it can link two other groups together. Typically it refers to -(CH 2 ) n - where n is 1-8 and preferably n is 1-4 , and the open valences need not be at opposite ends of a chain. Thus -CH(Me)- and -C(Me) 2 - may also be referred to as alkylenes. Where an alkylene group is substituted, the substituents include those typically present on alkyl groups as described herein.
  • any alkyl, alkenyl, alkynyl, acyl, or aryl or arylalkyl group or any of one of these groups that is contained in a substituent may itself optionally be substituted by additional substituents.
  • the nature of these substituents is similar to those recited with regard to the primary substituents themselves if the substituents are not otherwise described.
  • R 7 is alkyl
  • this alkyl may optionally be substituted by the remaining substituents listed as embodiments for R 7 where this makes chemical sense, and where this does not undermine the size limit provided for the alkyl per se; e.g., alkyl substituted by alkyl or by alkenyl would simply extend the upper limit of carbon atoms for these embodiments, and is not included.
  • each such alkyl, alkenyl, alkynyl, acyl, or aryl group may be substituted with a number of substituents according to its available valences; in particular, any of these groups may be substituted with fluorine atoms at any or all of its available valences.
  • Heteroform refers to a derivative of a group such as an alkyl, aryl, or acyl, wherein at least one carbon atom of the designated carbocyclic group has been replaced by a heteroatom selected from N, O and S.
  • the heteroforms of alkyl, alkenyl, alkynyl, acyl, aryl, and arylalkyl are heteroalkyl, heteroalkenyl, heteroalkynyl, heteroacyl, heteroaryl, and heteroarylalkyl, respectively. It is understood that no more than two N, O or S atoms are ordinarily connected sequentially, except where an oxo group is attached to N or S to form a nitro or sulfonyl group.
  • the group takes up two available valences, so the total number of substituents that may be included is reduced accordingly.
  • Halo as used herein includes fluoro, chloro, bromo and iodo. Fluoro and chloro are often preferred.
  • Amino refers to NH 2 , but where an amino is described as “substituted” or “optionally substituted”, the term includes NR'R" wherein each R' and R" is independently H, or is an alkyl, alkenyl, alkynyl, acyl, aryl, or arylalkyl group or a heteroform of one of these groups, and each of the alkyl, (alkenyl, alkynyl, acyl, aryl, or arylalkyl groups or heteroforms of one of these groups is optionally substituted with the substituents described herein as suitable for the corresponding group.
  • R' and R" are linked together to form a 3-8 membered ring which may be saturated, unsaturated or aromatic and which contains 1-3 heteroatoms independently selected from N, O and S as ring members, and which is optionally substituted with the substituents described as suitable for alkyl groups or, if NR'R" is an aromatic group, it is optionally substituted with the substituents described as typical for heteroaryl groups.
  • the compounds useful in the invention are derivatives of pyrimidine according to the general formula (I), as defined in claim 1 containing mandatory substituents at positions corresponding to the 2- and 4-positions of the pyrimidine ring.
  • the compounds include a 4-pyridylamine group at position 4 of the pyrimidine ring and a phenyl group at position 2 of the pyrimidine ring; each of these may be substituted.
  • the 4-pyridyl group may be a pyridine-N-oxide.
  • the compounds further include an amide group that is attached to the pyridyl ring at its position 3; this amide group is connected to the pyridyl ring through its carbonyl carbon.
  • the nitrogen of the amide may have one hydrogen and one non-hydrogen substituent, R 1 , attached to it, or it may be part of a ring formed by cyclizing R 1 onto a CH 2 group represented by R 2 . Accordingly, the compounds all share a common skeleton, and differ in the nature of certain optional substituents on the aryl rings and on the nitrogen of the carboxamide shown in formula (I).
  • the substituent R 1 of this carboxamide may be selected to avoid certain metabolic pathways that have been found to reduce the activity of certain compounds previously reported. Similarly, the substituents on R 1 may be selected to promote water solubility and bioavailability.
  • the present invention provides compounds less prone to such oxidation, such as compounds that incorporate an additional substituent on the portion of the amide containing this hydroxyl, in order to prevent or slow such oxidative metabolism. For example, by making the secondary alcohol into a tertiary alcohol, its oxidation is prevented.
  • the secondary hydroxyl is modified into an ether or an ester or a phosphate ester; and they may also serve as prodrugs of the secondary alcohol.
  • prodrugs can prolong delivery of the secondary alcohol by releasing the alcohol compound gradually in vivo as the prodrug undergoes metabolic cleavage to the free secondary alcohol, such as by ester or phosphate ester hydrolysis.
  • certain hydrogen bond donor substructures such as -OH and NH also can increase the effectiveness of the compounds of the invention, and are often suitably incorporated into the R 1 group of the amide in compounds of formula (I).
  • the incorporation of two such substructures into R 1 can enhance the activity of the compounds.
  • R 1 comprises a lactam or lactone ring, or a ketone carbonyl.
  • R 1 can be selected to improve bioavailability of the compounds of the invention, and in many embodiments it includes one or more polar functional groups such as those listed above. It may comprise an aromatic ring; however, in many embodiments where it represents an aryl or heteroaryl group, that group is a polar ring such as a phenyl substituted with an amide group, or a heteroaryl group such as a pyrrole or imidazole ring, or a cyclic amine. In other embodiments, R 1 incorporates one or more halo substituents on an alkyl group, such as for example a trifluoromethyl, which can improve water solubility and also deter metabolism.
  • polar functional groups such as those listed above. It may comprise an aromatic ring; however, in many embodiments where it represents an aryl or heteroaryl group, that group is a polar ring such as a phenyl substituted with an amide group, or a heteroaryl group such as a pyrrole or imid
  • R 1 is an alkoxy or heteroalkoxy, or a substituted amine group, with O or N directly bonded to the carboxamide nitrogen to form an acyl hydrazide or a hydroxamate derivative; an optionally substituted C1-C8 alkoxy or C1-C8 heteroalkoxy is sometimes preferred.
  • R 1 is an optionally substituted alkyl, cycloalkyl, heteroalkyl, acyl, heteroacyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl group.
  • R 1 is C1-C8 alkoxy, substituted amino, C1-C8 alkyl, C2-C8 heteroalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12-arylalkyl, or C6-C12 heteroarylalkyl, where each of the foregoing groups is optionally substituted by the substituents described herein as suitable for such groups.
  • R 1 includes a heterocyclic group having 3-8 ring members, at least one of which is a heteroatom selected from N, O and S; furanose and pyranose rings are sometimes included, and at other times a lactam, lactone, or 5-6 membered nonaromatic ring containing a nitrogen atom is included.
  • R in these substituents is independently H, C1-C8 alkyl, C2-C8 heteroalkyl, C6-C10 aryl, C5-C10 heteroaryl, C1-C8 acyl or C2-C8 heteroacyl.
  • Preferred embodiments of R 1 include C1-C8 alkyl and C2-C8 heteroalkyl , and each alkyl or heteroalkyl is optionally substituted as just described.
  • R 1 is of the form R 2 -C(OH)-CH 2 - or R-CH(OH)-CHR- or HO-CH 2 -CHR-, where each R is independently a C1-C8 alkyl or heteroalkyl group and may be substituted, and where two R groups can cyclize together to form a 3-8 membered ring that can include up to two heteroatoms selected form N, O and S as ring members.
  • R 1 comprises a substituted alkyl, cycloalkyl or heteroalkyl group that is preferably cyclic and is linked to the amide nitrogen through an aminoalkylene group such as -NR-(CH 2 ) 2-4 [N], where [N] represents the nitrogen of the carboxamide shown in formula (I).
  • R 1 can include in addition to the linkage -NR-(CH 2 ) 2-4 [N], a pyranose or furanose ring, which may be substituted and is in some instances substituted by one or more hydroxyl groups, preferably 2-4 hydroxyl groups, and which is either bonded directly to N of the linkage, or connected to that nitrogen by an optionally substituted C1-C4 alkylene or heteroalkylene linker such as (CH 2 ) 2-3 or -O(CH 2 ) 1-3 , each of which can be substituted.
  • a pyranose or furanose ring which may be substituted and is in some instances substituted by one or more hydroxyl groups, preferably 2-4 hydroxyl groups, and which is either bonded directly to N of the linkage, or connected to that nitrogen by an optionally substituted C1-C4 alkylene or heteroalkylene linker such as (CH 2 ) 2-3 or -O(CH 2 ) 1-3 , each of which can be substituted.
  • R 1 can comprise an aryl, heteroaryl, carbocyclic, or heterocyclic ring R n having 3-8 ring members, up to two of which can be heteroatoms selected from N, O and S, that is linked to the carboxamide of formula (I) through the above described aminoalkylene linker, e.g., R n -(CH 2 ) 0-2 -NR-(CH 2 ) 2-4 [N].
  • the ring R n or the linker connecting R n to the carboxamide nitrogen can include one or more ether linkages or be substituted with one or more substituents such as halo, hydroxyl, or C1-C4 alkoxy or an amino, C1-C4 alkylamino, or di-(C1-C4 alkyl)amino group.
  • R 1 comprises a linking aminoalkylene group such as -NR-(CH 2 ) 2-4 [N] as described above bonded to the carboxamide nitrogen
  • R 1 can comprise a sulfonyl, guanidinyl, or cyanoguanidinyl group attached through -NR-(CH 2 ) 2-4 [N] as described above for the acyl groups.
  • R 1 comprises a halogenated C1-C8 alkyl or heteroalkyl such as a polyfluorinated C1-C4 alkyl group, which can promote water solubility and slow metabolism.
  • R 1 includes compounds having a group such as CF 3 CF 2 (CH 2 ) 0-3 -NR-(CH 2 ) 2-4 [N] as R 1 .
  • R 1 comprises (CH 2 ) 3 -OR 4 or (CH 2 ) 3 -N(R 4 ) 2 .
  • each R 4 can be H or an optionally substituted C1-C20 hydrocarbyl group.
  • each R 4 is H or a C1-C4 alkyl, or N(R 4 ) 2 represents a 4-7 membered cyclic amine having up to two substituents suitable for an alkyl group and optionally including one additional heteroatom selected from N, O and S.
  • substituents may also be included on the pyrimidine, pyridine and aryl rings; in particular, the phenyl ring represented by Ar is optionally substituted with the groups described herein as suitable for placement on an aryl or heteroaryl ring, and may be substituted with 1-2 substituents selected from C1-C4 alkyl, C1-C4 alkoxy, CF 3 , halo, and CN in certain embodiments.
  • the pyridyl ring (which may be referred to as a nicotinamide, due to the presence of the 3-position amide group) can be substituted with up to three substituents suitable for placement on an aryl ring, so n can be 0-3.
  • n is 0 or 1 in formula (I).
  • the pyridyl ring of formula (I) is substituted with one group selected from C1-C4 alkyl, C1-C4 alkoxy, CF 3 , halo, and CN, and preferably selected from halo, methyl, CF 3 , and OMe.
  • the pyridyl ring is not substituted other than by the amide shown in formula (I), i.e., n is 0.
  • W include the substituents described herein as substituents for an aryl group generally. These include including halo, R, OR, NR 2 , SR, SO 2 R, SO 2 NR 2 , NRSO 2 R, NRCONR 2 , NRCOOR, NRCOR, CN, COOR, CONR 2 , OOCR, COR, and NO 2 , wherein each R is independently H, C1-C8 alkyl, C2-C8 heteroalkyl, C1-C8 acyl, C2-C8 heteroacyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C6-C10 aryl, or C5-C10 heteroaryl, and each R is optionally substituted with the same groups that may be present as substituents on the aryl group.
  • the pyrimidine ring may also be substituted with groups Y and Z at positions 5 and 6; these substituents are selected from those described herein as suitable for attachment to an aryl ring, and at least one such group is typically present, particularly at position 5.
  • Y and Z may independently be H, halo, OR, NR 2 , SR, -SOR, -SO 2 R, -OCOR, -NRCOR, -NRCONR 2 , -NRCOOR, -OCONR 2 , -COOR, SO 2 R, NRSOR, NRSO 2 R, -SO 3 R, -CONR 2 , SO 2 NR 2 , -CN, -CF 3 , or NO 2 , wherein each R is independently H, (1-8C) alkyl, (1-8C) heteroalkyl, (1-8C) acyl, (1-8C) heteroacyl, C6-C10 aryl, or C5-C10 heteroaryl and each R is optionally substituted with the same groups described above as suitable substituents for each group that comprises R.
  • Y is not H, so position 5 of the pyrimidine ring is generally substituted.
  • Y is selected from halo, OH, OR, NR 2 , and R, wherein each R is an optionally substituted group selected from C1-C8 alkyl, C1-C8 heteroalkyl, C6-C12 arylalkyl, and C6-C12 heteroarylalkyl, and where two R groups of NR 2 can optionally cyclize to form 3-8 membered ring containing 1-2 heteroatoms selected from N, O and S.
  • Preferred embodiments of Y include methoxy, ethoxy, propoxy, and isopropoxy; dimethylamino, pyrrolidin-1-yl, piperidine-1-yl, and morpholin-4-yl; and methyl, ethyl, propyl, isopropyl, cyclopropyl, t-butyl, cyclobutyl, and cyclopentyl.
  • Position 6 of the pyrimidine can also be substituted, so that Z can represent a substituent such as halo, NO 2 , or an optionally substituted member selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, acyl, and heteroacyl, or Z is NR 2 , wherein each R is independently H or an optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, acyl, heteroacyl, aryl or arylalkyl group or a heteroform of any of these groups. While position 6 of the pyrimidine can be so substituted, in many embodiments it is unsubstituted, i.e., Z represents H.
  • Z represents H.
  • Ar represents an optionally substituted phenyl; in many embodiments, Ar represents phenyl that is substituted with at least one and preferably two or more substituents selected from the group consisting of halo, CN, CF 3 , R, OR, NO 2 , SR, SO 2 R, NR 2 , and acyl, where each R is independently H, C1-C6 alkyl, C1-C8 acyl, or aryl.
  • Ar is substituted with at least one halo, and in certain embodiments it is substituted with 1-2 groups selected from C1-C4 alkyl, C1-C4-alkoxy, CF 3 , CN and halo; halo in such embodiments is sometimes preferably Cl or F.
  • Ar include phenyl substituted with F or Cl ortho to the carbon through which the phenyl is linked to the pyrimidine ring, which is referred to as position 2 for convenient reference.
  • Ar further comprises a second substituent which may also be halo at position 5.
  • a preferred embodiment for Ar which may be combined with the preferred features of each of the other structural components of the compound of formula (I), has F or Cl at position 2 and Cl or F at position 5 of the phenyl ring.
  • a subgroup of compounds of the invention according to the general formula (I), as defined in claim 1 are those compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein the compounds have the formula (II): and the salts, and stereoisomers thereof, wherein
  • Another subgroup of compounds of the invention according to the general formula (I), as defined in claim 1 are those compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein the compounds have the formula (III): and the salts, and stereoisomers thereof, wherein
  • any aryl, alkyl, cycloalkyl, heteroaryl, heteroalkyl, acyl, heteroacyl, arylalkyl, or heteroarylalkyl group included within a substituent may itself be substituted with the substituents typical for such groups. These substituents may occupy all available positions of the group, preferably 1-2 positions, or more preferably only one position.
  • the compounds of formula (I) may be supplied in the form of their pharmaceutically acceptable acid-addition salts including salts of inorganic acids such as hydrochloric, sulfuric, hydrobromic, or phosphoric acid or salts of organic acids such as acetic, tartaric, succinic, benzoic, salicylic, citric, alkylsulfonic, arylsulfonic, and glucuronic acids and the like. If a carboxyl moiety is present on the compound of formula (I), the compound may also be supplied as a salt with a pharmaceutically acceptable cation, such as sodium, potassium, or an ammonium salt.
  • a pharmaceutically acceptable cation such as sodium, potassium, or an ammonium salt.
  • any of the substituents of formula (I) contain chiral centers or rotational isomers (atropisomers), as some, indeed, do, the compounds of formula (I) include each stereoisomeric form thereof, both as an isolated stereoisomer and as a component of a mixture of these stereoisomeric forms.
  • Such mixtures of stereoisomers may be racemic or may be enriched in one enantiomer of a pair of enantiomers where a single chiral center is present.
  • the invention includes mixtures wherein either, neither or both centers are enriched in one stereoisomeric form.
  • a number of synthetic routes may be employed to produce the compounds of the invention. In general, they may be synthesized from conventional starting materials using reactions known in the art. Illustrative methods are provided below, and additional methods are described in published patent applications US 2004-0132159-A1 and US 2005/0004343-A1 .
  • Scheme 1 shows a general method for constructing pyrimidine rings having the substitution pattern required for compounds of the invention.
  • an amidine is prepared; these can typically be made from the corresponding aryl nitriles as illustrated.
  • the amidine is then allowed to react with a substituted malonaldehyde derivative to provide a 2-aryl substituted pyrimidinone.
  • the group represented by X in Scheme 1 is typically alkyl, aryl, cycloalkyl, alkoxy, or dialkylamino.
  • Scheme 2 illustrates a general strategy that was used to prepare many of the compounds of the invention, some of which are included in Table 1.
  • the pyrimidinone ring is produced by cyclizing an amidine moiety as shown above, and the pyrimidinone is converted into a 4-halopyrimidine, typically with thionyl chloride / DMF or with POCl 3 .
  • the halo group on the pyrimidine ring is then displaced by a 3-substituted 4-aminopyridine to obtain a versatile intermediate having a carboxylate ester on the pyridine ring.
  • This ester group is readily hydrolyzed to the free carboxylic acid as shown in Scheme 1, and then can easily be converted into a wide variety of carboxamides of the invention having the A group of formula (I) linked to the pyridyl ring through the carbonyl carbon.
  • the malonaldehydes required for this reaction are typically prepared by formylation of the corresponding esters, using LDA and ethyl formate. Using these conditions, compounds can readily be prepared wherein X represents an alkoxy, alkyl, aryl, heteroaryl, or dialkylamine, for example.
  • Reaction Schemes 3 and 4 shown below, provide routes to the pyrimidine nucleus that permit further substitution thereof.
  • a malonate or cyanoacetate derivative is used to form the pyrimidinones in Schemes 3 and 4 rather than the malonaldehyde derivative used above.
  • This provides pyrimidines having a substituent at position 6, corresponding to Z in formula (I).
  • Scheme 5 illustrates how the 3-carboxy-substituted-4-amino pyridines used in Scheme 2 above can be prepared via pyridine metalation chemistry.
  • the metalation introduces a carboxylic acid or ester adjacent to the protected 4-aminopyridine.
  • the 4-aminopyridine produced in this way can be coupled to an aryl pyrimidine as shown in Scheme 6, by cleaving the t-BOC from the amine substituent on the pyridine ring.
  • the ester can then be converted into the desired carboxamide by hydrolysis followed by amide formation shown in Scheme 6.
  • the ester can first be converted into a desired amide, and can then be attached to the halopyrimidine.
  • the former approach is often used, however, so that the preparation of a single carboxylic acid compound permits a wide variety of carboxamide products to be made, each in a single step using well-known amide formation conditions.
  • This scheme can be generally used to make 5-methoxypyrimidine compounds of the invention, and was employed to synthesize many of the compounds in Table 1. Furthermore, other 5-alkoxy derivatives are available from this scheme, because the methoxy group can be cleaved using lithium iodide in hot DMF as is known in the art.
  • the resulting hydroxypyrimidine can be O-alkylated or otherwise derivatized under conditions well known for the introduction of alkoxy, acyloxy, and similar substituents.
  • This scheme can be generally used to make isopropyl pyrimidines within the scope of the invention by coupling the carboxylic acid prepared in Scheme 7 with various amines.
  • the use of a palladium catalyst to effect the coupling of the aminopyridine to the chloropyrimidine can be avoided by the use of a stronger base such as sodium hexamethyldisilazane as described in the Examples below (see Example 3).
  • Scheme 8 depicts the preparation of a compound having a cyclopropyl group at position 5 of the pyrimidine ring. This method can be used to make 5-cyclopropyl pyrimidines having various carboxamide groups on the pyridine ring.
  • Scheme 9 depicts the corresponding synthesis of 5-cyclobutyl pyrimidine compounds, and shows the preparation of the methyl ester of cyclobutyl acetic acid from which the pyrimidine is constructed.
  • Scheme 10 shows the synthesis of 5-dimethylamino compounds of the invention using the same general approach. Cyclic amines can be introduced similarly.
  • Scheme 11 can be generally used to make benzyloxy pyrimidines, including ones with substitution on the benzyl group, as well as to make other alkoxy substituted compounds. Like the methoxy compounds, these benzyloxy compounds can be used to make other 5-O substituted compounds by removing the benzyl group using a catalytic hydrogenation, for example, followed by alkylation or acylation of the resultant hydroxypyrimidine.
  • Scheme 12 illustrates use of the methods described above for the preparation of compound of the invention where Y in formula (I) is a tert -butyl group.
  • the pyridine compounds can be oxidized to N-oxides using commonly known oxidation reagents such as, for example, meta-chloroperoxy benzoic acid or peracetic acid.
  • the present invention concerns a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as specified herein, or a compound of any of the subgroups of compounds of formula (I) as specified herein as defined in the claims, and a pharmaceutically acceptable carrier.
  • Said pharmaceutical composition is useful in the treatment of an infection with hepatitis C virus, by inhibiting-HCV replication
  • therapeutically effective amount means that amount of active compound or component or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought, in the light of the present invention, by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms, prophylactic activity, stabilization and/or reduction of the disease being treated.
  • compositions of the present invention may be formulated into various pharmaceutical forms for administration purposes.
  • compositions there may be cited all compositions usually employed for systemically administering drugs.
  • an effective amount of the particular compound, optionally an addition salt form thereof, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils and alcohols in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders and disintegrating agents in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • Injectable solutions may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • Injectable suspensions may also be prepared in which case appropriate liquid carriers and suspending agents may be employed.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
  • the compounds of the present invention may also be administered via oral inhalation or insufflation by means of methods and formulations employed in the art for administration via this way.
  • the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder, a solution being preferred. Any system developed for the delivery of solutions, suspensions or dry powders via oral inhalation or insufflation are suitable for the administration of the present compounds.
  • the present invention also provides a pharmaceutical composition adapted for administration by inhalation or insufflation through the mouth comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition adapted for administration by inhalation or insufflation through the mouth comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
  • the compounds of the present invention may be administered via inhalation of a solution in nebulized or aerosolized doses.
  • Unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and segregated multiples thereof.
  • an antiviral effective daily amount of a compound of formula (I) would be from 0.001 mg/kg to 500 mg/kg body weight, more preferably from 0.01 mg/kg to 50 mg/kg body weight, and even more preferably from 0.01 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the required dose as one, two, three, four or more (sub-)doses at appropriate intervals throughout the day. Said (sub-)doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.
  • the exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned hereinabove are therefore only guidelines.
  • the compounds of formula (I) show antiviral properties.
  • Viral infections and their associated diseases treatable using the compounds and methods of the present invention include those infections brought on by HCV and other pathogenic flaviviruses such as Yellow fever, Dengue fever (types 1-4), St. Louis encephalitis, Japanese encephalitis, Murray valley encephalitis, West Nile virus and Kunjin virus.
  • the diseases associated with HCV include progressive liver fibrosis, inflammation and necrosis leading to cirrhosis, end-stage liver disease, and HCC; and for the other pathogenic flaviviruses the diseases include yellow fever, dengue fever, hemorrhagic fever and encephalitis.
  • a number of the compounds of this invention moreover can be active against mutated strains of HCV.
  • the compounds of formula (I) or any subgroup thereof, their N -oxides, addition salts, or stereochemically isomeric forms are useful in the treatment of individuals experiencing a viral infection, particularly a HCV infection, and for the prophylaxis of these infections.
  • the compounds of the present invention may be useful in the treatment of warm-blooded animals infected with viruses, in particular flaviviruses such as HCV.
  • the compounds of the present invention or any subgroup thereof may therefore be used as medicines.
  • Said use as a medicine or method of treatment comprises the systemic administration to viral infected subjects or to subjects susceptible to viral infections of an amount effective to combat the conditions associated with the viral infection, in particular the HCV infection.
  • the present invention also relates to the use of the present compounds or any subgroup thereof according to the claims in the manufacture of a medicament for the treatment or the prevention of an infection with hepatitis C virus by inhibition of HCV replication.
  • amidine intermediates can be synthesized using lithium bis(trimethylsilyl)amide:
  • This intermediate can be used to make the carboxamide compounds of the invention by methods described herein: the 4-chloro substituent on the pyrimidine can be displaced by aminopyridines as described below.
  • BINAP 233mg, 0.375mmole
  • palladium(II)acetate 56.1mg, 0.25mmole were combined in 8ml dioxane (anh) and heated for 5 min, followed by addition of 2-(5-chloro-2-fluorophenyl)-4-chloro-5-isoprpylpyrimidine (1.42g, 5mmole), methyl 4-amino-3-pyridinecarboxylate (912mg, 6mmole) and cesium carbonate (2.28g , 7.0mmole). The mixture was heated to 90°C overnight. Removed dioxane under vacuum, the solid residue was triturated with ethyl acetate (20ml) and filtered to give 767mg product which contains cesium carbonate and was used directly in the next step without further purification.
  • the coupling can be achieved without using the palladium catalyst, if a stronger base is employed. This alternative is illustrated by the following example:
  • the chloropyrimidine (10 g, 35 mmol) and 4-amino-3-ester-pyridine (5.87 g, 38.6 mmol) were placed in an oven-dried flask (1 L), which was evacuated and flushed with nitrogen three times. Under nitrogen, anhydrous DMF (200 mL) was cannulated into the flask. Both materials were dissolved before the temperature was lowered to 0°C. Sodium hexamethyldisilazane (1M, 105 mL) in THF was then cannulated quickly into the solution. The mixture was stirred between 0°C and 15°C for 4 hrs. Saturated NH 4 Cl solution (100 mL) was then added and the solvent was evaporated under vacuum.
  • the imino chloro compound 1 (5g, 18.3 mmol, 1 eq), Pd 2 (dba) 3 (670 mg, 0.7 mmol, 0.04 eq) and BINAP (684 mg, 1.1 mmol, 0.06 eq) were suspended in dioxane (280 mL) under inert atmosphere.
  • a solution/ suspension of the amine 2 (3.07g, 20.2 mmol, 1.1 eq) in dioxane (90 mL) was added at a moderate speed, followed by Cs 2 CO 3 (11.9g, 36.5 mmol, 2 eq). The mixture was then heated to 95°C under nitrogen for 18 hours.
  • Cyclobutyl acetyl chloride (8.6g, 64.8mmole) was added dropwise to a stirred solution of pyridine (10.48m, 129.6 mmole) in methanol (105ml). The solution was stirred overnight at room temperature. Most of the excess methanol was removed under vacuum. Solution was poured onto 150ml water, extracted with diethyl ether (3x 125ml). Combined extracts were washed with 25ml 10% HCl, water (25ml) and saturated sodium bicarbonate (25ml), water (25ml), saturated sodium chloride (25ml).
  • 5-chloro-2-fluorobenzamidine (7.94g, 46.03mmol) was dissolved in 20ml tetrahydrofuran and added to the reaction mixture dropwise over 10 min. The mixture was then refluxed overnight. Removed most of the tetrahydrofuran under vacuum, and residue was taken up in 200ml water. Washed aqueous solution with diethyl ether (2 x 75ml) which removed dark color. Aqueous phase was acidified with glacial acetic acid to pH 5. Product precipitated from solution. Filtered solid, washed with water and vacuum dried to give 3.77g product. (29% yield).
  • the 5-benzyloxy analogs were synthesized using the same conditions as those for the 5-methoxy analogs, but using methyl-benzyloxyacetate 31 as the starting material.
  • reaction mixture was poured into 300ml ice water.
  • the organic layer was extracted with 1M sodium hydroxide (2 x 40ml) and added to the aqueous layer.
  • the aqueous layer was acidified with 40% sulfuric acid to pH 5.0 with cooling.
  • the solution was extracted with diethyl ether (5 x 40ml), combined ether extract washed with saturated sodium chloride, dried over sodium sulfate (anh.) and solvent removed to give product as a liquid (11.4g, 39% yield). This material was used without further purification.
  • BINAP (311mg, 0.50mmol) and palladium(II)acetate (74mg, 0.334mmol were combined in 10ml dioxane (anh.) and heated for 5 min, followed by addition of 2-(5-chloro-2-fluorophenyl)-4-chloro-5-t-butyllpyrimidine (2.00g, 6.68mmol), methyl 4-amino-3-pyridinecarboxylate (1.22g, 8.0mmol) and cesium carbonate (3.05g, 9.38mmol). The mixture was heated to 90°C overnight. Removed dioxane under vacuum, the solid residue was triturated with ethyl acetate (20ml) and filtered to give 3.15g product which contains cesium carbonate and was used directly in next step without further purification.
  • the ester (3.15g,) was suspended in 10ml methanol and treated with 4ml 2.0M NaOH (aq). The mixture was refluxed for 1 hour, then the cooled reaction mixture was concentrated under vacuum to remove methanol. The aqueous solution was acidified with 6M HCl (pH 5), and filtered to obtain product 2.25g.
  • the acid (100mg, 0.25mmole) was suspended in DMF (anh., 3ml) and treated with carbonyl diimidazole (81mg, 0.5mmole) and heated to 60°C for 2 hours.
  • S(+)-1-amino-2-propanol (75mg, 1.0mmole) was added and the solution was stirred overnight at room temperature. Filtered the mixture, and the filtrate was subjected to HPLC purification. Isolated 12mg product.
  • N-(3-aminopropyl)-4-[2-(5-chloro-2-fluoro-phenyl)-5-methoxy-5,6-dihydro-pyrimidin-4-ylamino]-nicotinamide (0.200 g) was dissolved in 2-propanol (20 mL) and diphenoxymethylenecyanamine (0.115) was added. The mixture stirred at 70°C for 8 h and then was cooled to rt.
  • ester 4-( ⁇ 4-[2-(5-Chloro-2-fluoro-phenyl)-5-methoxy-pyrimidin-4-yl-amino]-pyridine-3-carbonyl ⁇ -amino)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester (400mg) in 1 M NaOH (1 mL) and dioxane (6 mL) was heated at 60°C for 2.5 hours. 1 M HCl (2 mL) was added and the reaction mixture partitioned between water (50 mL) and CH2Cl2 (50 mL).
  • the dimethyl amide was formed from the carboxylic acid as described in Example 3 above.
  • Boc-protected amine 4-( ⁇ 4-[2-(5-chloro-2-fluoro-phenyl)-5-methoxy-pyrimidin-4-ylamino]-pyridine-3-carbonyl ⁇ -amino)-2-dimethylcarbamoyl-pyrrolidine-1-carboxylic acid tert-butyl ester (48 mg, 0.078 mmol) in 4 M HCL dioxane (2 mL) was stirred at room temperature for 3 hours. The solvent was removed in vacuo.
  • the compounds of formula (I) were examined for activity in the inhibition of HCV RNA replication in a cellular assay.
  • the assay demonstrated that the compounds of formula (I) exhibited activity against HCV replicons functional in a cell culture.
  • the cellular assay was based on a bicistronic expression construct, as described by Lohmann et al. (1999) Science vol. 285 pp. 110-113 with modifications described by Krieger et al. (2001) Journal of Virology 75: 4614-4624 , in a multi-target screening strategy. In essence, the method was as follows.
  • the assay utilized the stably transfected cell line Huh-7 luc/neo (hereafter referred to as Huh-Luc).
  • Huh-Luc This cell line harbors an RNA encoding a bicistronic expression construct comprising the wild type NS3-NS5B regions of HCV type 1b translated from an Internal Ribosome Entry Site (IRES) from encephalomyocarditis virus (EMCV), preceded by a reporter portion (FfL-luciferase), and a selectable marker portion (neo R , neomycine phosphotransferase).
  • IRS Internal Ribosome Entry Site
  • EMCV encephalomyocarditis virus
  • FfL-luciferase encephalomyocarditis virus
  • selectable marker portion neo R , neomycine phosphotransferase
  • the construct is bordered by 5' and 3' NTRs (non-translated regions) from HCV type 1b: Continued culture of the replicon cells in the presence of G418 (neo R ) is dependent on the replication of the HCV RNA.
  • the stably transfected replicon cells that express HCV RNA, which replicates autonomously and to high levels, encoding inter alia luciferase, are used for screening the antiviral compounds.
  • the replicon cells were plated in 384 well plates in the presence of the test and control compounds which were added in various concentrations. Following an incubation of three days, HCV replication was measured by assaying luciferase activity (using standard luciferase assay substrates and reagents and a Perkin Elmer ViewLux TM ultraHTS microplate imager). Replicon cells in the control cultures have high luciferase expression in the absence of any inhibitor. The inhibitory activity of the compound on luciferase activity was monitored on the Huh-Luc cells, enabling a dose-response curve for each test compound. EC 50 values were then calculated, which value represents the amount of the compound required to decrease by 50% the level of detected luciferase activity, or more specifically, the ability of the genetically linked HCV replicon RNA to replicate.
  • Table 1 lists compounds that were tested for activity in the inhibition of HCV RNA replication in a cellular assay according to the procedure described above.
  • Table 1 provides as well structure characterization data for the compounds of formula (I) as described herein.
  • the compounds in Table 1 are characterized in part by their biological activity and in part by their structure: the compounds were characterized in part by LC-mass spectrometry, and the second column of the Table provides the observed parent ion that was observed in the LC-MS analysis of the compounds that were prepared by the methods described above. In each case, the expected parent ion was observed, and the Table further provides the LC conditions under which the mass spectrum was measured as well as the retention time of the observed product.

Claims (7)

  1. Verwendung einer Verbindung der Formel (I) zur Herstellung eines Medikaments zur Behandlung einer Infektion mit Hepatitis-C-Virus, wobei die Verbindung die Formel (I) aufweist:
    Figure imgb0066
     wobei Ar für einen gegebenenfalls substituierten Phenylring steht;
    Y für H, Halogen, NO2 oder ein gegebenenfalls substituiertes Glied aus der Gruppe bestehend aus Alkyl, Cycloalkyl, Alkenyl, Alkinyl, Heteroalkyl, Heteroalkenyl, Heteroalkinyl, Aryl, Heteroaryl, Arylalkyl, Heteroarylalkyl, Acyl und Heteroacyl steht
    oder Y für NR2 stehen kann, wobei R jeweils unabhängig für H oder eine gegebenenfalls substituierte Alkyl-, Cycloalkyl-, Alkenyl-, Alkinyl-, Acyl-, Aryl- oder Arylalkylgruppe oder eine Heteroform einer dieser Gruppen steht und wobei zwei Gruppen R unter Bildung eines gegebenenfalls substituierten 3-8-gliedrigen heterocyclischen Ring cyclisieren können;
    R1 für eine gegebenenfalls substituierte Gruppe, die aus Alkyl, Cycloalkyl, Heteroalkyl, Acyl, Alkoxy, Alkylamino, Heteroacyl, Aryl, Heteroaryl, Arylalkyl und Heteroarylalkyl ausgewählt ist, steht, wobei jedes Heteroalkyl, Heteroacyl, Heteroaryl und Heteroarylalkyl ein oder mehrere Heteroatome, die aus O, N, S und P ausgewählt sind, enthält,
    mit der Maßgabe, dass R1 nicht für eine Gruppe der Formel -CH2-CH (OH) -R4 steht, wobei R4 für H oder eine gegebenenfalls substituierte Hydrocarbylgruppe, die kein Amin umfasst, steht;
    R2 für H steht oder R2 für CH2 steht und R1 und R2 unter Bildung eines gegebenenfalls substituierten Piperidin-, Morpholin- oder Piperazinrings oder eines Pyrrolidinrings, der durch mindestens einen Amino- oder Halogensubstituenten substituiert ist, cyclisieren;
    Z für H, Halogen, NO2 oder ein gegebenenfalls substituiertes Glied aus der Gruppe bestehend aus Alkyl, Cycloalkyl, Alkenyl, Alkinyl, Heteroalkyl, Heteroalkenyl, Heteroalkinyl, Aryl, Heteroaryl, Arylalkyl, Heteroarylalkyl, Acyl und Heteroacyl steht oder Z für NR2 steht,
    wobei R jeweils unabhängig für H oder eine gegebenenfalls substituierte Alkyl-, Cycloalkyl-, Alkenyl-, Alkinyl-, Acyl-, Heteroacyl-, Aryl- oder Arylalkylgruppe oder eine Heteroform einer dieser Gruppen steht;
    W jeweils unabhängig für Halogen, NR2, NO2, CN, CF3 oder ein gegebenenfalls substituiertes Glied aus der Gruppe bestehend aus Alkyl, Cycloalkyl, Alkenyl, Alkinyl, Heteroalkyl, Heteroalkenyl, Heteroalkinyl, Aryl, Heteroaryl, Acyl, Heteroacyl, Arylalkyl und Heteroarylalkyl steht,
    wobei R jeweils unabhängig für H oder eine gegebenenfalls substituierte Alkyl-, Cycloalkyl-, Alkenyl-, Alkinyl-, Acyl-, Aryl-, Heteroalkyl-oder Heteroarylgruppe steht;
    m für 0 oder 1 steht;
    n für 0-3 steht;
    und
    (a) Y aus der Gruppe bestehend aus einem 5-6-gliedrigen cyclischen Amin, OH, F, Cl, Br und I ausgewählt ist oder
    (b) m für 1 steht oder
    (c) R1 für OH oder ein gegebenenfalls substituiertes Alkoxy oder ein gegebenenfalls substituiertes Alkylamin steht oder
    (d) R2 für CH2 steht und R1 und R2 unter Bildung eines gegebenenfalls substituierten Piperidin-, Morpholin- oder Piperazinrings oder eines Pyrrolidinrings, der durch mindestens einen Amino-oder Halogensubstituenten substituiert ist, cyclisieren;
    (e) R1 C-NH2, ein Nitril, ein Lactam oder einen Lactonring oder ein Keton oder ein gegebenenfalls substituiertes 4-5-gliedriges cyclisches Amin umfasst oder
    (f) R1 mindestens zwei Unterstrukturen umfasst, die unabhängig aus der Gruppe bestehend aus:
    (1) C-NH-C,
    (2) C-OH,
    (3) C=O,
    (4) P=O,
    (5) S=O,
    (6) C=N,
    (7) einem nicht cyclischen Ether-Sauerstoff,
    (8) einem tertiären nicht acylierten Amin,
    (9) einem 5-6-gliedrigen aromatischen oder heteroaromatischen Ring,
    (10) C-X, wobei X aus OH, Cl und F ausgewählt ist,
    (11) CT-O-R4, wobei CT für einen Kohlenstoff, der an drei andere Kohlenstoffatome gebunden ist, steht und R4 für H oder eine gegebenenfalls substituierte Hydrocarbylgruppe steht, und
    (12) einem gegebenenfalls substituierten 3-bis 8-gliedrigen carbocyclischen Ring ausgewählt sind oder
    (f) R1-(CH2)3-OR4 oder -(CH2)2-N(R4)2 umfasst, wobei R4 jeweils unabhängig für H oder eine gegebenenfalls substituierte Hydrocarbylgruppe steht;
    oder ein pharmazeutisch unbedenkliches Salz davon.
  2. Verwendung nach Anspruch 1, wobei Ar für ein substituiertes Phenyl steht.
  3. Verwendung nach Anspruch 1, wobei Ar durch 1-2 Gruppen, die aus Halogen, C1-C4-Alkyl, CN, CF3 und C1-C4-Alkoxy ausgewählt sind, substituiert ist.
  4. Verwendung nach einem der Ansprüche 1-3, wobei n für 0 oder 1 steht.
  5. Verwendung nach einem der Ansprüche 1-3, wobei Z für H steht.
  6. Verwendung nach Anspruch 5, wobei Y aus der Gruppe bestehend aus Halogen, OH, OR, NR2 und R ausgewählt ist, wobei R jeweils für eine gegebenenfalls substituierte Gruppe, die aus C1-C8-Alkyl, C1-C8-Heteroalkyl, C6-C12-Arylalkyl und C6-C12-Hetero-arylalkyl ausgewählt ist, steht und wobei zwei Gruppen R von NR2 gegebenenfalls unter Bildung eines 3-8-gliedrigen Rings mit 1-2 Heteroatomen, die aus N, O und S ausgewählt sind, cyclisieren können.
  7. Verwendung nach Anspruch 1, wobei die Verbindung die Formel (II) aufweist:
    Figure imgb0067
     und die Salze davon, wobei
    R1, R2, Y und m wie in Anspruch 1 definiert sind;
    Ar für ein Phenyl, das gegebenenfalls durch ein oder zwei Halogene substituiert ist, steht.
EP07820916.0A 2006-10-04 2007-10-04 Carboxamid 4-[(4-pyridyl)amino] pyrimidine zur behandlung von hepatitis c Active EP2097084B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07820916.0A EP2097084B1 (de) 2006-10-04 2007-10-04 Carboxamid 4-[(4-pyridyl)amino] pyrimidine zur behandlung von hepatitis c

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06121756 2006-10-04
EP07820916.0A EP2097084B1 (de) 2006-10-04 2007-10-04 Carboxamid 4-[(4-pyridyl)amino] pyrimidine zur behandlung von hepatitis c
PCT/EP2007/060539 WO2008040778A2 (en) 2006-10-04 2007-10-04 Carboxamide 4-[(4-pyridyl)amino] pyrimidines for the treatment of hepatitis c

Publications (2)

Publication Number Publication Date
EP2097084A2 EP2097084A2 (de) 2009-09-09
EP2097084B1 true EP2097084B1 (de) 2015-01-28

Family

ID=37808226

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07820916.0A Active EP2097084B1 (de) 2006-10-04 2007-10-04 Carboxamid 4-[(4-pyridyl)amino] pyrimidine zur behandlung von hepatitis c

Country Status (6)

Country Link
US (1) US9987277B2 (de)
EP (1) EP2097084B1 (de)
JP (1) JP5616063B2 (de)
CA (1) CA2665438C (de)
ES (1) ES2535212T3 (de)
WO (1) WO2008040778A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201019939A (en) 2008-08-20 2010-06-01 Schering Corp Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734486A1 (en) * 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
ES2439009T3 (es) 2008-08-20 2014-01-21 Merck Sharp & Dohme Corp. Derivados de piridina y pirimidina sustituidos con etenilo y su uso en el tratamiento de infecciones virales
WO2010022125A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
EP2536410B1 (de) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituierte pyrimidinderivate und ihre verwendung bei der behandlung viraler infektionen
ES2813875T3 (es) 2014-01-01 2021-03-25 Medivation Tech Llc Compuestos y procedimientos de uso
KR102633122B1 (ko) 2014-08-01 2024-02-05 누에볼루션 에이/에스 브로모도메인에 대하여 활성을 갖는 화합물
KR20180114910A (ko) 2016-02-05 2018-10-19 데날리 테라퓨틱스 인크. 수용체-상호작용 단백질 키나제 1의 억제제
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
CN1116288C (zh) 1996-04-23 2003-07-30 沃泰克斯药物股份有限公司 用作肌苷－5'－一磷酸脱氢酶抑制剂的脲衍生物
PT966465E (pt) 1997-03-14 2003-11-28 Vertex Pharma Inibidores do enzima imfdh
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
KR100652535B1 (ko) 1999-03-19 2006-12-01 버텍스 파마슈티칼스 인코포레이티드 Ｉｍｐｄｈ 효소의 억제제
US7087399B1 (en) * 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
JP4794793B2 (ja) 1999-12-28 2011-10-19 ファーマコペイア， インコーポレイテッド Ｎ−ヘテロ環ＴＮＦ−α発現阻害剤
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
GB0127433D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
KR100516434B1 (ko) * 2002-04-04 2005-09-22 (주) 비엔씨바이오팜 6-(4-치환된-아닐리노)피리미딘 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
WO2004024159A1 (en) 2002-09-10 2004-03-25 Scios Inc. INHIBITORS OF TFGβ
WO2004078207A1 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
US7223766B2 (en) * 2003-03-28 2007-05-29 Scios, Inc. Bi-cyclic pyrimidine inhibitors of TGFβ
WO2005117885A1 (en) * 2004-06-04 2005-12-15 Bioniche Life Sciences Inc. Use of imatinib to treat liver disorders and viral infections
US8030318B2 (en) * 2005-03-25 2011-10-04 Tibotec Pharmaceuticals Ltd. Fused bicyclic inhibitors of HCV
US20060281763A1 (en) * 2005-03-25 2006-12-14 Axon Jonathan R Carboxamide inhibitors of TGFbeta

Also Published As

Publication number Publication date
CA2665438C (en) 2014-12-02
EP2097084A2 (de) 2009-09-09
JP5616063B2 (ja) 2014-10-29
JP2010505797A (ja) 2010-02-25
WO2008040778A3 (en) 2009-01-29
CA2665438A1 (en) 2008-04-10
US9987277B2 (en) 2018-06-05
ES2535212T3 (es) 2015-05-06
US20090247523A1 (en) 2009-10-01
WO2008040778A2 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
EP2097084B1 (de) Carboxamid 4-[(4-pyridyl)amino] pyrimidine zur behandlung von hepatitis c
EP1869037B1 (de) Heterobicyclische inhibitoren von hvc
JP5046942B2 (ja) Ｈｃｖ阻害性の二環式ピリミジン類
CN103282360B (zh) Cxcr4受体拮抗剂
CN102099036B (zh) 用于治疗炎性疾患和纤维化疾患的化合物和方法
CN101203515B (zh) 用作HCV抑制剂的吡啶并[2,3-d]嘧啶类及其制备方法
EP1840122B1 (de) Aminopyrimidinverbindungen und ihre salze, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US20070066632A1 (en) Fused bicyclic inhibitors of TGFbeta
WO2006105222A2 (en) Carboxamide inhibitors of tgfb
UA71951C2 (en) Pyrimidines as sorbitol dehydrogenase inhibitors, a pharmaceutical composition containing them, intermediate compounds and a method for the preparation of intermediate compound
JP6170944B2 (ja) Ｈｃｖ阻害剤としてのヘテロ−二環式誘導体
JP6916796B2 (ja) Ｎｉｋ阻害剤としての新たな６員のヘテロ芳香族置換シアノインドリン誘導体
EP1549316A1 (de) HEMMER VON TFG&bgr;
EP2953462B1 (de) Tetracyclische heterocyclische verbindungen sowie verfahren zur verwendung davon zur behandlung von hepatitis c
US6608058B2 (en) 6-methylnicotinamide derivatives as antiviral agents
US10807983B2 (en) Imidazo-fused heterocycles and uses thereof
EP2953461B1 (de) Tetracyclische heterocyclische verbindungen sowie verfahren zur verwendung davon zur behandlung von hepatitis c
EP3964509B1 (de) Verbindung mit kondensiertem ring, verwendung davon und pharmazeutische zusammensetzung damit
EP2448584B1 (de) Substituierte 4-hydroxypyrimidin-5-carboxamide
CN101171014B (zh) 可用作hcv抑制剂的蝶啶类物质及其制备方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090617

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TIBOTEC PHARMACEUTICALS

17Q First examination report despatched

Effective date: 20091111

R17C First examination report despatched (corrected)

Effective date: 20100108

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JANSSEN R&D IRELAND

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/14 20060101ALI20140813BHEP

Ipc: A61K 31/506 20060101AFI20140813BHEP

Ipc: A61K 31/535 20060101ALI20140813BHEP

INTG Intention to grant announced

Effective date: 20140901

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007040198

Country of ref document: DE

Effective date: 20150312

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 707937

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150315

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: JANSSEN SCIENCES IRELAND UC

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2535212

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150506

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 707937

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150128

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20150128

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150428

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150528

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150429

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007040198

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20151029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602007040198

Country of ref document: DE

Owner name: JANSSEN SCIENCES IRELAND UC, LITTLE ISLAND, IE

Free format text: FORMER OWNER: JANSSEN R&D IRELAND, EASTGATE, LITTLE ISLAND, IE

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20160707 AND 20160713

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602007040198

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20071004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20170913

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20170927

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20171013

Year of fee payment: 11

Ref country code: ES

Payment date: 20171102

Year of fee payment: 11

Ref country code: GB

Payment date: 20171004

Year of fee payment: 11

Ref country code: SE

Payment date: 20171011

Year of fee payment: 11

Ref country code: IT

Payment date: 20171024

Year of fee payment: 11

Ref country code: IE

Payment date: 20171010

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150128

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20180913

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007040198

Country of ref document: DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20181004

REG Reference to a national code

Ref country code: BE

Ref legal event code: FP

Effective date: 20150424

Ref country code: BE

Ref legal event code: MM

Effective date: 20181031

Ref country code: BE

Ref legal event code: PD

Owner name: JANSSEN SCIENCES IRELAND UC; IE

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), AUTRE, FORM 2544; FORMER OWNER NAME: JANSSEN R&D IRELAND

Effective date: 20150423

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181005

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181004

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181004

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181004

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20191129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031